NARA Discovery
Article Details
← Back to Search Results
Journal Article

Psychedelic use and psychiatric risks

Otto Simonsson; Simon B. Goldberg; Richard Chambers; Walter Osika; Charlotta Simonsson; Peter S. Hendricks
Psychopharmacology · Vol. 242, Issue 7 · pp. 1577-1583 · 2025

Abstract

Rationale Research on psychedelics has recently shown promising results in the treatment of various psychiatric disorders, but relatively little remains known about the psychiatric risks associated with naturalistic use of psychedelics. Objective The objective of the current study was to investigate associations between naturalistic psychedelic use and psychiatric risks. Methods Using a sample representative of the US adult population with regard to sex, age, and ethnicity ( N =2822), this study investigated associations between lifetime naturalistic psychedelic use, lifetime unusual visual experiences, and past 2-week psychotic symptoms. Results Among respondents who reported lifetime psychedelic use ( n =613), 1.3% reported having been told by a doctor or other medical professional that they had hallucinogen persisting perception disorder. In covariate-adjusted linear regression models, lifetime psychedelic use was associated with more unusual visual experiences at any point across the lifetime, but no association was observed between lifetime psychedelic use and past 2-week psychotic symptoms. There was an interaction between lifetime psychedelic use and family (but not personal) history of psychotic or bipolar disorders on past 2-week psychotic symptoms such that psychotic symptoms were highest among respondents who reported lifetime psychedelic use and a family history of psychotic or bipolar disorders and lowest among those who reported lifetime psychedelic use and no family history of psychotic or bipolar disorders. Conclusions Although the results in this study should be interpreted with caution, the findings suggest that lifetime naturalistic use of psychedelics might be associated with more unusual visual experiences across the lifetime, as well as more psychotic symptoms in the past 2 weeks for individuals with a family history of psychotic or bipolar disorders and the reverse for those without such a family history. Future research should distinguish between different psychotic and bipolar disorders and should also utilize other research designs (e.g., longitudinal) and variables (e.g., polygenic risk scores) to better understand potential cause-and-effect relationships.

Bibliographic Information

JournalPsychopharmacology
PublisherSpringer
Publication Date2025-07-01
Publication Year2025
Volume242
Issue7
Pages1577-1583
Document TypeJournal Article
Print ISSN0033-3158
eISSN1432-2072
DOI10.1007/s00213-023-06478-5

Access Information

NARA Access Coverage1959-01-01~Current
Journal Homepagehttps://www.springer.com/journal/213
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.